Source list – HerCare

Learn about Menopause:
Darj, S. Nilsson, O. Axelsson, D. Hellberg, Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women, Maturitas, Volume 13, Issue 2, 1991, Pages 109-115
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996 Feb 7;275(5):370-5. doi: 10.1001/jama.1996.03530290040035. PMID: 8569016.
Ettinger B: ”Reduced mortality associated with long-term postmenopausal estrogen therapy.” Obstetrics and Gynecology jan. 1996;87(1):6-12.
Fitzpatrick LA m. fl: ”Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey.” Journal of Women’s Health Gender Based Medicine maj 2000;9(4):381-387
Fournier A, Berrino F, Clavel-Chapelon F: ”Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.” Breast Cancer Research and Treatment årgång 107, nr 1 jan. 2008:103-111.
L’hermite, M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013; 16: 44–53
Learn about Perimenopause:
Cornelius Schüle, Caroline Nothdurfter, Rainer Rupprecht, The role of allopregnanolone in depression and anxiety, Progress in Neurobiology, Volume 113, 2014,
de Lignières B. Oral micronized progesterone. Clin Ther. 1999 Jan;21(1):41-60; discussion 1-2. doi: 10.1016/S0149-2918(00)88267-3. PMID: 10090424.
Freeman EW. Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population. Womens Midlife Health. 2015 Aug 11;1:2. doi: 10.1186/s40695-015-0002-y. PMID: 30766689; PMCID: PMC6214217.
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):149–157. doi:10.1001/jamapsychiatry.2017.3998
Hernández-Hernández OT, Martínez-Mota L, Herrera-Pérez JJ, Jiménez-Rubio G. Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression. Curr Neuropharmacol. 2019;17(5):459-471. doi: 10.2174/1570159X16666180628165107. PMID: 29956632; PMCID: PMC6520586.
Prior JC. Progesterone for Symptomatic Perimenopause Treatment – Progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011;3(2):109-20. PMID: 24753856; PMCID: PMC3987489.
Prior JC, Hitchcock CL. The endocrinology of perimenopause: need for a paradigm shift. Front Biosci (Schol Ed). 2011 Jan 1;3(2):474-86. doi: 10.2741/s166. PMID: 21196391.

Our four hormonal states:
Frackiewicz EJ, Shiovitz TM. Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder. J Am Pharm Assoc (Wash). 2001 May-Jun;41(3):437-47. doi: 10.1016/s1086-5802(16)31257-8. PMID: 11372908.
Gudipally PR, Sharma GK. Premenstrual Syndrome. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560698/
Stearns S. PMS and PMDD in the domain of mental health nursing. J Psychosoc Nurs Ment Health Serv. 2001 Jan;39(1):16-27. doi: 10.3928/0279-3695-20010101-10. PMID: 11197992.
Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac Rev. 2022 Apr 28;11:11. doi: 10.12703/r/11-11. PMID: 35574174; PMCID: PMC9066446.